{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T06:58:44Z","timestamp":1790492324354,"version":"4.1.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T00:00:00Z","timestamp":1785715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Urol"],"DOI":"10.1038\/s41585-026-01180-5","type":"journal-article","created":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:44:21Z","timestamp":1785757461000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Beyond surgical technique: modifiable risk factors and evolving treatment paradigms in bladder cancer surgery"],"prefix":"10.1038","author":[{"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Rosiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0595-7165","authenticated-orcid":false,"given":"Andrea","family":"Salonia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3007-2756","authenticated-orcid":false,"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,3]]},"reference":[{"key":"1180_CR1","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1038\/s41585-025-01098-4","volume":"23","author":"M Egger","year":"2026","unstructured":"Egger, M. et al. Optimizing local control in the surgical management of bladder cancer. Nat. Rev. Urol. 23, 266\u2013282\u00a0https:\/\/doi.org\/10.1038\/s41585-025-01098-4 (2026).","journal-title":"Nat. Rev. Urol."},{"key":"1180_CR2","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1007\/s00345-024-04970-x","volume":"42","author":"F Pellegrino","year":"2024","unstructured":"Pellegrino, F. et al. Peri- and post-operative outcomes of robot-assisted radical cystectomy after the implementation of the EAU guidelines recommendations for collecting and reporting complications at a high-volume referral center. World J. Urol. 42, 270\u00a0https:\/\/doi.org\/10.1007\/s00345-024-04970-x (2024).","journal-title":"World J. Urol."},{"key":"1180_CR3","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1097\/JU.0000000000002988","volume":"209","author":"LC McLoughlin","year":"2023","unstructured":"McLoughlin, L. C. et al. Obesity and complication risk from radical cystectomy: identifying a body mass index threshold. J. Urol. 209, 111\u2013120\u00a0https:\/\/doi.org\/10.1097\/JU.0000000000002988 (2023).","journal-title":"J. Urol."},{"key":"1180_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2026.05.010","author":"J Kohler","year":"2026","unstructured":"Kohler, J. et al. Survival association of GLP-1 receptor agonists and SGLT2 inhibitors in bladder cancer patients. Urol. Oncol. https:\/\/doi.org\/10.1016\/j.urolonc.2026.05.010 (2026).","journal-title":"Urol. Oncol."},{"key":"1180_CR5","doi-asserted-by":"publisher","first-page":"103408","DOI":"10.1016\/j.eclinm.2025.103408","volume":"87","author":"SK Kamarajah","year":"2025","unstructured":"Kamarajah, S. K. et al. Evaluation of safety of preoperative GLP-1 receptor agonists in patients undergoing elective surgery: a systematic review, meta-analysis and meta-regression. eClinicalMedicine 87, 103408\u00a0https:\/\/doi.org\/10.1016\/j.eclinm.2025.103408 (2025).","journal-title":"eClinicalMedicine"},{"key":"1180_CR6","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","volume":"394","author":"C Vulsteke","year":"2026","unstructured":"Vulsteke, C. et al. Perioperative enfortumab vedotin and pembrolizumab in bladder cancer. N. Engl. J. Med. 394, 1257\u20131269\u00a0https:\/\/doi.org\/10.1056\/NEJMoa2511674 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1180_CR7","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa2601486","volume":"395","author":"MD Galsky","year":"2026","unstructured":"Galsky, M. D. et al. Enfortumab vedotin and pembrolizumab in cisplatin-eligible bladder cancer. N. Engl. J. Med.\u00a0395, 338\u2013348 https:\/\/doi.org\/10.1056\/NEJMoa2601486 (2026).","journal-title":"N. Engl. J. Med."},{"key":"1180_CR8","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S1470-2045(26)00050-1","volume":"27","author":"A Necchi","year":"2026","unstructured":"Necchi, A. et al. Neoadjuvant sacituzumab govitecan plus pembrolizumab, followed by adjuvant pembrolizumab, in patients with muscle-invasive bladder cancer (SURE-02): a single-arm, phase 2 study. Lancet Oncol. 27, 442\u2013451\u00a0https:\/\/doi.org\/10.1016\/S1470-2045(26)00050-1 (2026).","journal-title":"Lancet Oncol."},{"key":"1180_CR9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-26-00142","author":"A Necchi","year":"2026","unstructured":"Necchi, A. et al. Neoadjuvant sacituzumab govitecan in patients with muscle-invasive bladder cancer: primary results of the SURE-01 trial. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/JCO-26-00142 (2026).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Reviews Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01180-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01180-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01180-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T11:44:22Z","timestamp":1785757462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41585-026-01180-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,3]]},"references-count":9,"alternative-id":["1180"],"URL":"https:\/\/doi.org\/10.1038\/s41585-026-01180-5","relation":{},"ISSN":["1759-4812","1759-4820"],"issn-type":[{"value":"1759-4812","type":"print"},{"value":"1759-4820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,3]]},"assertion":[{"value":"3 August 2026","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}